Immunohistochemical assessment of the tumour-associated epitopes CD44v6 and E48 in tumour-free lymph nodes from patients with squamous cell carcinoma in the head-neck region

Eva-Maria Fabriciusa, Michael Guschmannb, Angelika Langforda, Berthold Hell a and Jürgen Bierna

a Clinic for Maxillofacial Surgery, Medical Faculty of the Humboldt University of Berlin, Charité, Campus Virchow Hospital, Berlin, Germany
b Institute of Pathology, Medical Faculty of the Humboldt University of Berlin, Charité, Campus Virchow Hospital, Berlin, Germany

Received 26 June 1999
Accepted 28 February 2000

We examined immunohistochemically 370 tumour-free lymph nodes from 41 patients with a head and neck squamous cell carcinoma (HNSCC) to clarify whether the tumour-associated epitopes CD44v6 and E48 are suitable for adjuvant postoperative immunotherapy. All the positively immunostained cells found were single cells.

CD44v6+ cells were found in 55% of the lymph nodes, with their numbers increasing in pN>0-patients (62%). Only pN>0-patients had abundant to massive CD44v6+ cells. A comparison with mononuclear cells in lymphatic tissue from control patients suggested a similarity with activated T-cells. In the 41 cancer patients there were significantly fewer lymph nodes with E48+ cells (11%), but the number of E48+ cells increased in pN>1-patients (29%) with predominantly abundant E48+ cells. We conclude from the comparison with the epithelial marker EMA that the E48+ single cells are epithelial in origin. Only a specific E48 peptide sequence appears suitable for adjuvant immunotherapy in patients with head-neck tumours.

Keywords: Carcinoma-free lymph nodes, CD44v6, E48, immunohistochemistry, APAAP

1. Introduction

Squamous cell carcinomas of the head and neck tend to recurrence and secondary tumours. Worldwide, fewer than 50% of these patients survive disease five years or longer [54]. For the postoperative therapy it is crucial to detect any disseminated carcinoma cells [2,3,24,30,51,53,55]. Adjuvant radio-chemotherapy targets only cells which are in the process of proliferation and division. The majority of the disseminated carcinoma cells may be non-proliferative (G0 phase) and therefore escape the effects of this therapy [23,51,53]. This has prompted a search on the one hand for methods to detect disseminated cells in tumour free lymph nodes in patients with head-neck tumours and on the other hand for suitable immunological therapies to eliminate them [2,3,11,12,24,38,52].

Our purpose is to choose a target epitope for an adjuvant immunotherapy with the aid of an immunohistochemical characterization of head-neck tumours. Investigations up to now of primary tumours and lymph node metastases have achieved a good presentation with the help of monoclonal antibodies against the tumour associated markers CD44v6 and E48 [26,27]. We demonstrated both epitopes on the carcinoma cells on every primary tumour and in lymph node metastases, most frequently on pG1 tumours and significantly down-regulated on pG3 tumours.
CD44v6 is a splice variant of the ubiquitous adhesion molecule CD44, which is considered as a metastasis marker for certain tumours [31,32] and can also be used to characterize among others, tumours of the head and neck region [34–36,57,67]. E48 was isolated from a head-neck tumour [62,63,68]. Research to date has found E48 only in normal and malignant keratinocytes, in squamous cell carcinomas and transitional epithelia [6,68]. Antibodies against CD44v6 (viz U36 [34]) and E48 are already being successfully applied in radio/immunoscintigraphy and in the radio/immunotherapy of head-neck tumours [8–10,25,34].

Since the lymphogenic dissemination of cancer cells is crucial in carcinoma metastasis, we subjected all extirpated tumour-free lymph nodes from 41 head-neck tumour patients to an immunohistochemical examination using the monoclonal antibodies against CD44v6 and E48. With these antibodies we had examined the primary tumours and their lymph node metastases in previous studies [26,27]. To elucidate the results, we also used various other antibodies against epithelial epitopes and against mononuclear cells. We compared the findings in tumour-free lymph nodes from our 41 head neck tumour patients and with these lymphatic tissues from non-tumour control patients (normal and inflamed lymphatic tissue such as spleen, tonsils and lymph nodes from other diseases).

2. Material and methods

2.1. Patients

From 41 head and neck tumour patients in our clinic from 1994 to 1997, we examined all 370 surgically extirpated lymph nodes located close to a primary squamous cell carcinoma. These lymph nodes had been histopathologically determined to be without carcinoma. 34 of the patients were men (average age 56 years) and 7 women (average age 67 years). Five additional lymph nodes from 4 of these patients, which according to routine histopathology were free of metastases, had to be evaluated separately (Table 1), so that our study proper comprised 370 carcinoma-free lymph nodes. The patients had received neither radio- nor chemotherapy preoperatively. The lymph nodes examined were extirpated on the same day as the primary tumours. The patients’ further course of disease (recurrence, secondary tumour, death) was correlated with the CD44v6 and E48 findings in the tumour-free lymph nodes. To verify our findings, we selected archival lymphatic tissues from 30 control patients without malignant tumours: Table 2.
Table 1
Study of 370 tumour-free lymph nodes from 41 patients with squamous cell carcinoma in the head and neck region*

| Tumour sites                  | Number of patients without regional lymph node metastases (pN0)/number of tumour-free lymph nodes | Number of patients with regional lymph node metastases (pN1)/number of tumour-free lymph nodes |
|------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| floor of mouth               | 8/57                                                                                           | 2/39                                                                                           |
| floor of mouth/tongue        | 8/55                                                                                           | 1/1                                                                                           |
| tongue                       | 3/10                                                                                            | 2/12                                                                                            |
| buccal mucous membrane       | 3/42                                                                                            | 1/22                                                                                            |
| ear                          | 1/11                                                                                            | 1/1                                                                                           |
| lip                          | 2/10                                                                                            | –                                                                                              |
| tonsil                       | –                                                                                               | 1/20                                                                                            |

Grading

| Grading | Number of patients without regional lymph node metastases (pN0)/number of tumour-free lymph nodes | Number of patients with regional lymph node metastases (pN1)/number of tumour-free lymph nodes |
|---------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| pG1     | 4/37                                                                                            | –                                                                                              |
| pG2     | 16/104                                                                                          | 3/35                                                                                            |
| pG3     | 5/44                                                                                            | 5/70                                                                                            |

Tumour spread

| Tumour spread | Number of patients without regional lymph node metastases (pN0)/number of tumour-free lymph nodes | Number of patients with regional lymph node metastases (pN1)/number of tumour-free lymph nodes |
|---------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| T1            | 9/60                                                                                            | 1/11                                                                                            |
| T2            | 9/67                                                                                            | 2/21                                                                                            |
| T3            | 2/21                                                                                            | 2/33                                                                                            |
| T4            | 5/37                                                                                            | 3/40                                                                                            |

Total

|                      | Number of patients without regional lymph node metastases (pN0)/number of tumour-free lymph nodes | Number of patients with regional lymph node metastases (pN1)/number of tumour-free lymph nodes |
|----------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
|                      | 25/185                                                                                          | 8/105                                                                                            |

*In another 5 lymph nodes from 4 of these 41 patients we detected immunohistochemically occult micrometastases with monoclonal antibodies CD44v6 and E48 and scored these separately from the immunohistochemically carcinoma-free lymph nodes: cf. 2.3.2 and Fig. 5.

Table 2
Study of lymphatic control tissues for comparison

| Tissues examined                                      | Number of control patients |
|-------------------------------------------------------|----------------------------|
| Tuberculous lymph nodes with epithelioid cell granulomas | 10                         |
| Lymph nodes with non-specific inflammation            | 10                         |
| Tonsils with tonsillitis                              | 6                          |
| Normal spleen                                         | 2                          |
| Spleen with perisplenitis                             | 2                          |
| Total                                                 | 30                         |

2.3.2. Immunohistochemical examination of carcinoma cells in the micrometastases

We detected 5 lymph nodes from 4 patients with cells, which had formed as a micrometastasis (cf. footnote in Table 1). For the evaluation of the micrometastases, we confined the assessment to the carcinoma cells in them [26]. The expression of CD44v6 and E48 was scored by multiplying the staining intensity (SI) of the carcinoma cells by the percentage of positive carcinoma cells (PP) [65]. For comparison, the 5 micrometastases and the 20 lymph node metastases of the same 41 patients [26] were immunohistochemically stained with a series of epithelial antibodies against cytokeratin and epithelial membrane antigens (cf. Table 3) and calculated exclusively as immunoreactive scores of the carcinoma cells [65], cf. [26,27].

2.4. Statistical evaluation

The immunohistochemical results of the CD44v6⁺ and E48⁺ single cells in the tumour-free lymph nodes were calculated for their statistical significance with the χ²-test [66]. For the statistical comparison of expression in micrometastases and lymph node metastases, the t-test or the U-test by Mann and Whitney were used [66]. Calculations were made with the statistics program SigmaStat for Windows Version 1.0 (Jan-
Table 3

Antibodies used to compare with the detected CD44v6$^+$ and/or E48$^+$ cells in carcinoma-free lymph nodes (cf. Table 1) and to examine various lymphatic control tissues (cf. Table 2)

| Antibodies/Manufacturer | Pretreatment of paraffin sections | Detection of |
|-------------------------|----------------------------------|--------------|
| Ck MNF116/DAKO          | mw and proteinase K              | Ck-10, Ck-17, Ck-18 |
| 1:25 M0821              |                                  |              |
| EMA/DAKO                | mw                               | epithelial membrane antigen |
| 1:20 M0613              |                                  |              |
| Ber-EP4/DAKO            | mw and proteinase K              | epithelial antigen |
| 1:50 0804              |                                  |              |
| Ck-4/BOEHRINGER         | mw                               | Ck-4         |
| 1:50 1273 370           |                                  |              |
| Ck-5/6/BOEHRINGER       | mw and proteinase K              | Ck-5, Ck-6   |
| 1:10 1273 396           |                                  |              |
| Ck-7/DAKO               | mw and proteinase K              | Ck-7         |
| 1:100 M7018             |                                  |              |
| Ck-8/PROGEN             | mw and proteinase K              | Ck-8         |
| 1:2000 61031            |                                  |              |
| Ck-17/DAKO              | mw and proteinase K              | Ck-17        |
| 1:5 M7046               |                                  |              |
| Ck-18/SIGMA             | mw                               | Ck-18        |
| 1:400 C1399             |                                  |              |
| Ck-19/DAKO              | mw and proteinase K              | Ck-19        |
| 1:20 M0888              |                                  |              |
| Ck-19/DAKO              | mw and proteinase K              | Ck-19        |
| 1:20 M772               |                                  |              |
| CD4/DAKO                | mw                               | CD4$^+$ T cells |
| (CD45RO) M0834          |                                  |              |
| 1:500                   |                                  |              |
| CD8/DAKO                | mw                               | CD8$^+$ T cells |
| 1:100 M7103             |                                  |              |
| CD68/DAKO               | mw and proteinase K              | monocytes and macrophages |
| 1:2000 M0814            |                                  |              |

del Scientific, Erkrath, Germany). We correlated the occurrence of CD44v6$^+$ and/or E48$^+$ cells with the further course of the patients’ disease in the Kaplan–Meier curve using the SPSS program for Microsoft Windows Version 6.1 (SPSS Inc., Chicago, USA).

3. Results

3.1. Detection of CD44v6$^+$ and/or E48$^+$ single cells in carcinoma-free lymph nodes in patients with a squamous cell carcinoma of the head and neck region

Of the 370 tumour-free lymph nodes from the 41 patients with a head neck tumour (cf. Table 1 and Fig. 1), we demonstrated positively immunostained single cells in 211 lymph nodes. CD44v6$^+$ single cells were found in 205 lymph nodes, and E48$^+$ single cells in 41 lymph nodes: Table 4, Fig. 1 (cf. 2.3.1). In 34 of the 205 lymph nodes with CD44v6$^+$ cells we also found E48$^+$ cells. In 6 lymph nodes with E48$^+$ cells, no CD44v6$^+$ cells were present. The number of lymph nodes with stained cells was higher for both markers in patients with a lymph node metastasis than in pN0 patients. However, CD44v6$^+$ cells were demonstrated most frequently in patients with pN1 (pN1:pN>1 = 70%:51%; p = 0.01). E48$^+$ cells were detected most frequently in pN>1 patients (pN<1:pN>1 = 6%:29%; p < 0.001).
E.-M. Fabricius et al. / Assessment of the tumour-associated epitopes 119

Fig. 1. Results of the examination of 370 tumour-free lymph nodes (LN) in patients with squamous cell carcinoma in the head-neck region. CD44v6+ single cells were present in 205 lymph nodes and E48+ single cells in 41 lymph nodes. Altogether, we found stained single cells in 211 lymph nodes (cf. Table 4). In most of the lymph nodes we found solitary to scattered distribution of stained single cells (rated with 1+). Abundant to massive numbers (rated with 2+) of CD44v6+ single cells were not present in lymph nodes from pN0 patients and abundant to massive numbers of E48+ single cells were found solely in lymph nodes from pN>1 patients.

Table 4

| CD44 v6+ | E48+ |
|----------|------|
| Lymph nodes with stained single cells/total number of lymph nodes | 205/370 | 41/370 |
| pN0 patients | 91/185 | 16/185 |
| pN>0 patients | 114/185 | 25/185 |
| pN1 patients | 73/105 | 2/105 |
| pN>1 patients | 41/80 | 23/80 |

Number of stained cells in the lymph nodes:

Solitary to scattered distribution of stained cells (1+):

- pN0 patients: 154/205, 26/41
- pN>0 patients: 63/185, 10/185
- pN1 patients: 37/105, 2/105
- pN>1 patients: 26/80, 8/80

Abundant to massive distribution (2+):

- pN0 patients: 51/205, 15/41
- pN>0 patients: 0/185, 0/185
- pN1 patients: 51/185, 15/185
- pN>1 patients: 36/105, 0/105

In the carcinoma-free lymph nodes, the number of CD44v6+ cells was significantly higher than that of E48+ cells: 55% and 11% ($p < 0.001$), respectively. Table 4 and Fig. 1 clearly show that we found immunostained single cells in carcinoma-free lymph nodes from pN0 patients less frequently than in carcinoma-free lymph nodes from pN>0 patients. However, the difference is significant only with CD44v6 for pN0: pN>0 = 49% : 62% ($p = 0.025$), by contrast for E48 = 9% : 14% ($p > 0.05$). The number of stained single cells in the lymph nodes increased significantly with both markers from pN0 to pN>1 patients ($p < 0.001$). In none of the pN0 patients did we detect abundant to massive stained single cells (evaluation 2+; cf. 2.3.1). Notably, abundant to massive presence of CD44v6+ cells was demonstrated in lymph nodes from pN1 patients more frequently than in pN>1 patients (34% : 19%). By contrast, we found abundant to massive numbers of E48+ cells only in pN>1 patients (19%). All of the CD44v6+ and/or E48+ cells thus evaluated were single cells, as opposed to cells separately specified positive, which were to be found in small cell clusters and were identified histopathologically as micrometastases (cf. 2.3.2 and 3.5).

3.2. Examination of the CD44v6+ and E48+ cells with various epithelial antibodies as a control procedure

Altogether, 211 carcinoma-free lymph nodes contained CD44v6+ and/or E48+ single cells (cf. Table 4 and Fig. 1). We examined these lymph nodes immunohistochemically with the antibodies against epithelial
markers (cytokeratin and membrane markers listed in Table 3) using APAAP and evaluated the stained single cells using the same method as with CD44v6+ and E48+, cf. 2.3.1. Figure 2 shows that cells immunostained with epithelial markers were demonstrated only in a few lymph nodes with Ck-MNF 116, EMA, and Ck-4, and these were usually only solitary, positively stained single cells. Only in one pN1 patient did we demonstrate along with many CD44v6+ cells an abundance of stained EMA-cells. The E48 immunostain was negative in the lymph nodes of this patient. Neither in terms of location or morphology were the EMA cells identical to the CD44v6+ cells. By comparison, 44% of tumour-free lymph nodes with E48+ cells had EMA+ cells located in a similar position. All other epithelial antibodies (Table 3) were non-reactive.

3.3. Examination of the lymphatic control tissues with the monoclonal antibodies CD44v6, E48 and all control antibodies (Table 3)

To elucidate the origin of the CD44v6+ and E48+ cells, we examined 30 control tissue specimens (cf. Table 2). In the spleens and tonsils examined we found neither CD44v6+ nor E48+ cells. We did however find CD44v6+ cells in the tuberculous lymph nodes as well as in non-specifically inflamed lymph nodes. The proportion of positively stained cells in these lymphatic tissues was significantly higher than in the 370 tumour-free lymph nodes. It attained the highest proportion in the tuberculous lymph nodes, in particular in epithelioid cell granulomas of these lymph nodes. 80% of the lymph nodes with non-specific lymphadenitis contained CD44v6+ cells, albeit in smaller numbers than in the tuberculous lymph nodes. The CD44v6+ cells in tuberculous lymph nodes were compared with the immunohistochemical reaction of the diverse antibodies (cf. Table 3): Fig. 3. All multinuclear Langhans giant cells were CD44v6+ but were negative with all epithelial markers. The reaction of the monoclonal antibody CD44v6+ in the tuberculous lymph nodes, in particular in epithelioid cell granulomas, was partially comparable to the reaction of cells stained by the monoclonal antibody CD4. Unlike CD8+ cells, which prefer to settle in the outer boundary of the epithelioid cell granuloma, CD4+ and CD44v6+ cells prefer the inner boundary of the granulomas. Outside the granuloma and in other regions of the lymph nodes, we did however demonstrate, as a rule, more CD4+ cells than the significantly smaller number of CD44v6+ cells. Moreover, the multinuclear Langhans giant cells were CD44v6+, while there was no staining by CD4. In contrast to CD44v6+ and CD4+ cells, CD8+ cells were settled predominantly in the centre of epithelioid cell granulomas in the tuberculous lymph nodes. Abundant to massive numbers of CD68+ cells (monocytes and macrophages) were distributed over the entire lymph node, including the epithelioid cell granuloma, and were present in greater numbers than were CD44v6+ cells.

E48+ cells were detected neither in the inflamed lymph nodes, nor in the epithelioid cell granulomas of the tuberculous lymph nodes. In particular in epithelioid cell granulomas of these lymph nodes, 80% of the lymph nodes with non-specific lymphadenitis contained CD44v6+ cells, albeit in smaller numbers than in the tuberculous lymph nodes. The CD44v6+ cells in tuberculous lymph nodes were compared with the immunohistochemical reaction of the diverse antibodies (cf. Table 3): Fig. 3. All multinuclear Langhans giant cells were CD44v6+ but were negative with all epithelial markers. The reaction of the monoclonal antibody CD44v6+ in the tuberculous lymph nodes, in particular in epithelioid cell granulomas, was partially comparable to the reaction of cells stained by the monoclonal antibody CD4. Unlike CD8+ cells, which prefer to settle in the outer boundary of the epithelioid cell granuloma, CD4+ and CD44v6+ cells prefer the inner boundary of the granulomas. Outside the granuloma and in other regions of the lymph nodes, we did however demonstrate, as a rule, more CD4+ cells than the significantly smaller number of CD44v6+ cells. Moreover, the multinuclear Langhans giant cells were CD44v6+, while there was no staining by CD4. In contrast to CD44v6+ and CD4+ cells, CD8+ cells were settled predominantly in the centre of epithelioid cell granulomas in the tuberculous lymph nodes. Abundant to massive numbers of CD68+ cells (monocytes and macrophages) were distributed over the entire lymph node, including the epithelioid cell granuloma, and were present in greater numbers than were CD44v6+ cells.

E48+ cells were detected neither in the inflamed lymph nodes, nor in the epithelioid cell granulomas of the tuberculous lymph nodes. In particular in epithelioid cell granulomas of these lymph nodes, 80% of the lymph nodes with non-specific lymphadenitis contained CD44v6+ cells, albeit in smaller numbers than in the tuberculous lymph nodes. The CD44v6+ cells in tuberculous lymph nodes were compared with the immunohistochemical reaction of the diverse antibodies (cf. Table 3): Fig. 3. All multinuclear Langhans giant cells were CD44v6+ but were negative with all epithelial markers. The reaction of the monoclonal antibody CD44v6+ in the tuberculous lymph nodes, in particular in epithelioid cell granulomas, was partially comparable to the reaction of cells stained by the monoclonal antibody CD4. Unlike CD8+ cells, which prefer to settle in the outer boundary of the epithelioid cell granuloma, CD4+ and CD44v6+ cells prefer the inner boundary of the granulomas. Outside the granuloma and in other regions of the lymph nodes, we did however demonstrate, as a rule, more CD4+ cells than the significantly smaller number of CD44v6+ cells. Moreover, the multinuclear Langhans giant cells were CD44v6+, while there was no staining by CD4. In contrast to CD44v6+ and CD4+ cells, CD8+ cells were settled predominantly in the centre of epithelioid cell granulomas in the tuberculous lymph nodes. Abundant to massive numbers of CD68+ cells (monocytes and macrophages) were distributed over the entire lymph node, including the epithelioid cell granuloma, and were present in greater numbers than were CD44v6+ cells.

E48+ cells were detected neither in the inflamed lymph nodes, nor in the epithelioid cell granulomas of
Fig. 3. Immunohistochemical comparison of CD44v6 in tuberculous control lymph nodes with the expression of other markers (Table 3). In non-specifically inflamed lymph nodes (cf. Table 2) – not mentioned here – we found smaller numbers of stained cells than in tuberculous lymph nodes. The reaction in tuberculous lymph nodes and non-specifically inflamed lymph nodes was negative with other antibodies and with E48 – also not mentioned here. In the normal spleens, in spleens with perisplenitis and in the tonsils with tonsillitis no positively stained single cells were demonstrated.

Table 5
Postoperative course of disease in the 41 patients participating in the study with squamous cell carcinoma of the head and neck region (cf. Fig. 4)

|                          | Number of patients with relapse* | Number of patients without relapse |
|--------------------------|----------------------------------|-----------------------------------|
| Patients with lymph nodes containing CD44v6+ single cells (cf. 2.3.1): | 15 | 14 |
| lymph nodes with solitary to scattered distribution of CD44v6+ cells (1+) | 12 | 11 |
| lymph nodes with abundant to massive CD44v6+ cells (2+) | 3 | 3 |
| Patients with lymph nodes lacking CD44v6+ cells: | 7 | 5 |
| Patients with lymph nodes containing E48+ single cells (cf. 2.3.1): | 7 | 3 |
| lymph nodes with solitary to scattered distribution of E48+ cells (1+) | 5 | 2 |
| lymph nodes with abundant to massive E48+ cells (2+) | 2 | 1 |
| Patients with lymph nodes lacking E48+ cells: | 15 | 16 |

*Relapse, secondary tumour, metastasis or death.

3.4. Possible role of CD44v6+ and E48+ cells for the further course of tumour disease

Follow-up data on the 41 cancer patients in this study up to the first appearance of relapse (recurrence, secondary tumour, metastasis or death) is recorded in Table 5. This was compared to the demonstration of CD44v6+/CD44v6− cells (Fig. 4a) and E48+/E48− cells (Fig. 4b) in the carcinoma-free lymph nodes using the Kaplan–Meier curve. Patients with CD44v6+ cells in the lymph nodes suffered relapse with a distinct but still statistically insignificant delay compared to patients without CD44v6+ cells in the lymph nodes (20 months as opposed to 11 months ($p > 0.05$)). The onset of relapse did not significantly differ between patients with E48+ single cells in the lymph nodes (20 months) and those without E48+ cells (17 months): $p > 0.1$.

3.5. Detection of occult micrometastases

Using the monoclonal antibodies against CD44v6 and E48 we detected small occult micrometastases in 5 lymph nodes from 4 patients (10% of the patients) among the original total of 375 lymph nodes (1%). These 5 lymph nodes were carcinoma-free in routine histopathology using the hematoxylin–eosin staining. In the micrometastases, only the carcinoma cells were evaluated in the same manner as were the primary
tumours or lymph node metastases [26,27]. We estimated the immunoreactive cancer cell scores of the 5 micrometastases (cf. 2.3.2 [65]), both for CD44v6 and E48 and for the epithelial antibodies (cf. Table 3) and compared these results with the immunoreactive scores for the 20 lymph node metastases presented in Fig. 5. The immunoreactive scores of the carcinoma cells with the markers CD44v6 and E48, particularly with CD44v6, were generally higher than the epithelial antibody scores for cytokeratin and membrane markers. This was the case both with the percentage of positively stained carcinoma cells and with the immunostaining intensity.

Regarding the micrometastases, the mean immunoreactive score for CD44v6 was significantly higher than that for E48 ($p = 0.01$) and for all epithelial markers ($p < 0.001$). In the same manner, in the 20 lymph node metastases the CD44v6 scores diverged statistically from the E48 scores ($p < 0.01$) and from the scores of all other epithelial markers (cytokeratin MNF116, epithelial membrane antigen (EMA): $p < 0.025$; all other markers: $p < 0.01$). By contrast, the scores of the epithelial markers and of E48 were not statistically different, either for the 5 micrometastases ($p > 0.1$) or for the 20 lymph node metastases ($p > 0.05$).

4. Discussion

Fifty percent of all patients with head-neck tumours suffer recurrence or secondary tumour [54]. This could be attributable to the fact that malignant molecular changes in the resection margins escape histopatholog-

---

**Fig. 4.** Postoperative course of disease in patients with squamous cell carcinoma in the head and neck region using the Kaplan–Meier curves: (a) Comparison of patients with CD44v6$^+$ and of patients without CD44v6$^+$ cells in tumour-free lymph nodes. The onset of relapse was not significantly later in patients with positive cells ($p > 0.05$). (b) Comparison of patients with E48$^+$ and of patients without E48$^+$ cells in tumour-free lymph nodes. The onset of relapse was not significantly later in patients without positive cells ($p > 0.1$).
The further course of disease could also be determined by disseminated carcinoma cells not detected in histopathology, for example in lymph nodes.

Only with the immunohistochemical and molecular-biological characterization both of the invasive tumour fronts and of the tumour-free margins did it become possible to elaborate new prognostic criteria for squamous cell carcinoma of the head and neck to supplement histopathology. Primarily the parameters of proliferative activity and apoptosis are evaluated [13–17,44,56,58–60]. Even subclinical molecular changes should be given adjuvant therapy [39].

Clinical observations and model investigations have shown that with the development of a primary tumour its metastatic spread has already begun [19,28,29,41,43,69,73], and since the end of the 1980’s the dissemination of epithelial cells in mesenchymal surroundings (bone marrow, lymph nodes or blood) has been investigated [11,12,24,30], cf. [21,51–53,61]. Since disseminated carcinoma cells are mostly found outside the cell cycle in the G0 phase [23,51,53], they elude both the postoperative radiotherapy and chemotherapy of head-neck tumour patients. These cells might however be of significance for the further course of disease. This failure to catch the G0 carcinoma cells at this early stage could be a reason why head-neck tumours show a high rate of recurrence or secondary carcinomas.

With the aim of finding an adjuvant active immunotherapy, the expression of the tumour-associated adhesion molecules CD44v6 and E48 was investigated in the histopathologically tumour free lymph nodes of patients with a squamous cell carcinoma of the head and neck region. Our efforts, in concurrence with those of other authors [34,48,70,72], cf. [47], were directed towards the postoperative elimination of dormant carcinoma cells with a target-associated adjuvant cytotoxic immunotherapy. In a former head-neck tumour study we characterized 60 tumours and 20 lymph node metastases of patients with a squamous cell carcinoma in this region [26,27]. These examinations yielded results concurrent with other authors [35,36,57,63,67,68] – the markers CD44v6 and E48 appear on all primary tumours and lymph node metastases of head-neck tumour patients. However, like Hyckel et al. [36] and Salmi et al. [67], we encountered different parts of positive carcinoma cells and the colour intensity on the cells, depending on the tumour grade, and obtained different immunoreactive scores cf. [65] for the tumours and metastases. Poorly differentiated tumours showed a downregulation of both epitopes. With the monoclonal antibody CD44v6 we obtained significantly higher scores for squamous cell carcinoma of the head-neck region than with the monoclonal antibody E48.

In this study we investigated whether cells of different histogenesis carry the epitope CD44v6 and/or E48 in tumour-free lymph nodes. By comparison with different antibodies and by examination of various lymphatic tissues we attempted to classify the stained cells. The successful classification of the stained cells is crucial for establishing the best peptide for a spe-
4.1. Significance of CD44v6+ single cells in carcinoma-free lymph nodes of patients with head-neck tumour

In 205 of the 370 tumour-free lymph nodes (55%) we discovered isolated to massive numbers of CD44v6+ single cells: Table 4 and Fig. 1. It is conceivable that the more frequent evidence of CD44v6+ cells and the increased number of CD44v6+ single cells in tumour-free lymph nodes compared to E48+ single cells in the same tumour-free lymph nodes (9%; cf. 4.2) is related to the stronger expression of the epitope CD44v6 found both in the primary tumour and lymph node metastasis of the same patient [26,27].

We included the expression of different other markers in this study (cf. Table 3) to help clarify the question of whether all the cells which stained positive are of epithelial origin, particularly since CD44v6 is also present on various hematopoietic cells [4,42]. Since the CD44v6+ cells in the carcinoma-free lymph nodes are non-contiguous single cells in a scattered to crowding distribution, it can be excluded that they could be micrometastases. Although labeling with epithelial antibody (Table 3) did not show detectable staining of the same cells by CD44v6 in carcinoma-free lymph nodes, it cannot be ruled out that some few of the CD44v6+ cells are epithelial (cf. Fig. 2), even if we cannot definitively prove this for certain with our epithelial markers. Positively stained single cells in these lymph nodes could have escaped observation, as they were very few in number and stained only minimally with the less sensitive epithelial markers. This low sensitivity of the epithelial markers was observed in our investigation of micrometastases and lymph node metastases (Fig. 5).

In patients with lymph node metastasis, the number of carcinoma-free lymph nodes with CD44v6+ cells and the number of CD44v6+ cells in the carcinoma-free lymph nodes increased compared to the findings in pN0 patients (Fig. 1 and Table 4). Contrary to E48 (cf. 4.2), there were not significantly more CD44v6+ cells in lymph nodes of pN>1 patients than in pN1 patients. We also found lymph nodes with abundant numbers of CD44v6+ cells more frequently in pN1 patients than in pN>1 patients (49% : 37%). This may indicate some form of a reduced local immunoreaction to advanced tumour growth.

Another objection that might be raised is that the CD44v6+ cells as demonstrated in tumour-free lymph nodes were not as a rule epithelial cells. In the tuberculous lymph nodes we found abundant individual CD44v6+ cells in the epithelioid cell granulomas (Fig. 3). The location of the CD44v6+ cells in the epithelioid cell granulomas corresponded virtually to that of CD4+ cells. Both were settled primarily near the inner boundary of the epithelioid cell granulomas cf. [40]. In the tuberculous lymph node, where they stained with equal intensity, we found far more CD4+ than CD44v6+ cells outside the granuloma. While the monoclonal antibody CD45RO which we used predominantly marks activated lymphocytes, it also marks naive lymphocytes. Notably, fewer than 1% of naive lymphocytes in lymph nodes express CD44v6 [75], cf. [50]. This fact, along with the somewhat reduced number of CD44v6+ cells in comparison to CD4+ cells, leads to the tentative conclusion that cells which express both CD4 and CD44v6 are activated T-lymphocytes. Arch et al. [4], cf. [42] were able to inhibit activated T-lymphocytes with anti-CD44v6-antibodies, cf. [46]. According to the findings by Wittig et al. [74,75], CD44+ lymphocytes are TH1 cells. Their essential role for cell-mediated immunity is known [1], cf. [47,75].

It is important to note the diverse settlement of CD8+ cells in the granulomas in and outside the outer boundary and also throughout the entire tuberculous lymph node at sites not settled by the CD44v6+ cells. Similarly, the comparison with the staining of the macrophage-monocyte marker CD68 revealed, as anticipated, that the number and distribution of CD68+ cells were only partially identical with that of the CD44v6+ cells. CD68+ cells were distributed in abundance entirely throughout all of the tuberculous lymph nodes. Finally, we demonstrated CD44v6+ cells in non-specifically inflamed lymph nodes as well, albeit in smaller quantities than in the tuberculous lymph nodes.

We believe that the CD44v6+ single cells in carcinoma-free lymph nodes signal a basic activation of the local immunodefenses, similar to a milder or stronger cell-mediated defense. According to Wittig et al. [74, 75], cf. [46], CD44v6+ cells point to a synergistic process of activated T-helper cells and macrophages as a sort of delayed type of immunoreaction. This might ex-
plain the further course of disease (Fig. 4a and Table 5). Patients with CD44v6+ cells had fewer relapses and relapsed later than did patients without CD44v6+ cells. In order to confirm the presence of CD44v6+ cells in tumour-free lymph nodes as an available marker for local immune response to the tumour we want to proceed with our study on a larger group of head and neck tumour patients. The application of the CD44v6-peptide does not appear to be acceptable for the development of postoperative active immunotherapy. However, van Hal et al. [34] have introduced the monoclonal anti-U36 antibody – which is largely identical to CD44v6 – as a suitable candidate for passive immunotherapy. It is conceivable that success or failure of active immunotherapy in eliminating disseminated tumour cells or in interfering with the cell-mediated immune response to the tumour might in the end trigger the phenomenon of immunological enhancement of tumour growth.

4.2. Significance of the E48+ cells in carcinoma-free lymph nodes of patients with head-neck cancer

In 34 out of the 370 tumour-free lymph nodes (9%) we detected E48+ single cells: Table 4 and Fig. 1. E48 has been demonstrated to date only on keratinocytes, transitional epithelia and on squamous cells and/or on their malignant counterparts [6,63,68]. This is corroborated by the fact that we found E48+ cells in contrast to CD44v6 neither in tuberculous epithelioid cell granulomas nor in non-specifically inflamed lymph nodes. In the carcinoma-free lymph nodes the number of lymph nodes with E48+ single cells rose markedly from pN0 to pN>1 patients and only in pN>1 patients with advanced disease did we find abundant E48+ cells. On the basis of our findings we would suggest that the E48+ single cells may be disseminated tumour cells which have not yet formed into a micrometastasis.

In the 34 tumour-free lymph nodes with E48+ single cells we were unable to demonstrate with the epithelial antibodies (cf. Table 3) that the E48+ single cells were epithelial cells. Only with the antibodies against the epithelial membrane antigen (EMA, cf. Table 3) could we detect in 44% of the same tumour-free lymph nodes EMA+ single cells in comparable location and with comparable morphology. The other epithelial markers were negative (Fig. 3). We know, on the one hand, however, that EMA not only marks epithelial cells but is also expressed on normal lymph-cells [5,18,22,45]. And on the other hand, the comparison of the immunohistochemical demonstration of epithelial markers on the 20 lymph node metastases with E48 revealed that the immunohistochemical scores of the epithelial marker in the paraffin sections are lower than those for E48 (cf. Fig. 5). Evidence of single cells positive with epithelial markers was rarer in the 34 tumour-free lymph nodes with E48+ single cells. This could be attributable to the lower sensitivity of the epithelial markers. Nonetheless by way of analogy we would draw a cautious conclusion from our findings that the E48+ single cells in the tumour-free lymph nodes are most likely epithelial cells as are possibly disseminated carcinoma cells.

Regarding the further course of disease in patients with E48+ single cells (Fig. 4b and Table 5), the Kaplan–Meier curve is very similar to that of patients without E48+ cells. Relapse became evident in 70% of the patients with E48+ cells and only in 48% of the patients without these cells (no significance: \( p > 0.1 \)). There was no evidence that recurrence was more frequent in patients with demonstrated E48 single cells, or that these cells influenced the further course of disease. Given that only 41 cancer patients were involved in our study, this observation must be verified with a larger patient population.

4.3. Detection of micrometastases in lymph nodes from patients with head neck cancer by the monoclonal antibodies CD44v6 and E48

It is well known that in routine histopathology the chances of detecting a micrometastasis of 3 cell diameter in one section of the hematoxylin and eosin (HE) staining is 1:100 [33]. As a rule, in routine histopathology only one section of each extirpated lymph node is evaluated. We evaluated three sections per lymph node with our two markers CD44v6 and E48 and were able to detect 5 micrometastases from 4 patients from among the 375 lymph nodes originally judged to be tumour-free (cf. Table 1). The perceptable staining intensity of both markers in immunohistochemistry confirmed this discovery. We were able to ascertain that with both monoclonal antibodies CD44v6 and E48 micrometastases could be well marked immunohistochemically, somewhat better with CD44v6 than the 20 lymph node metastases (Fig. 5). We used both the 5 micrometastases and the 20 lymph node metastases to evaluate our findings from the tumour-free lymph nodes in order to determine the immunoreactive sensitivity of several epithelial markers in paraffin sections (cf. Table 3). The immunoreactive score was significantly higher in the mi-
crometastases with CD44v6 than with E48 ($p = 0.01$). This was less pronounced in the 20 lymph node metastases ($p < 0.025$). Figure 5 shows that micrometastases and lymph node metastases cannot be demonstrated as well with the epithelial markers used as with CD44v6 and E48 ($p < 0.001$). We deduce from this that the reduced sensitivity of the epithelial markers also pertains to the immunohistochemical proof of disseminated single cells.

It is evident that the further course of disease can be determined by a very few disseminated carcinoma cells [49]. Highly sensitive markers are therefore being sought to recognize micrometastases and to eliminate them therapeutically [2,3,11,12,21,24,38,49,71]. Nevertheless, the interpretation and significance of individual cells which have been demonstrated to be occult metastases remains controversial [11,21,33,37]. A sufficiently extended postoperative observation period and an adequate number of patients are necessary to be able to evaluate the findings.

4.4. Conclusions

Our findings in carcinoma-free lymph nodes from patients with squamous cell carcinoma of the head and neck region emphasize that for a postoperative immunotherapy a peptide sequence of E48 seems more appropriate than CD44v6 despite better immunohistochemic characterization by CD44v6 of squamous cell carcinomas of the head and neck region and of lymph node metastases [26,27]. It remains to be seen to what extent a E48-specific RT-PCR with a substantially higher sensitivity would prove superior in finding of disseminated carcinoma single cells [7,24]. To screen for suitable patients for the postoperative immunotherapy with a E48-peptide vaccine, we envisage continuing our histopathologic examination of lymph nodes without metastasis using a E48-specific RT-PCR.

Acknowledgements

This work was supported by the European Science Foundation (ESF).

We are indebted to Prof. Warnaar, Vice President of Cancer Research, CENTOCOR B.V. (Leiden, The Netherlands) for the generous gift of the monoclonal antibody E48 used in this study.

We thank Prof. Dr. G.-P. Wildner, Robert-Rössle-Clinic, Berlin and Prof. Dr. H. Lobeck, Institute of Pathology, “Ernst von Bergmann” Clinic, Potsdam, for critical evaluation of a number of histologic sections and for helpful discussion of results as well as Dr. W. Schmidt’s statistical evaluation (Max Delbrueck Center, Berlin). The skilled immunohistochemical techniques were carried out by Mrs. U. Kruse-Boitschenko and we also acknowledge Mrs. C. Aubel’s secretarial support.

References

[1] A.K. Abbas, K.M. Murphy and A. Sher, Functional diversity of helper T lymphocytes, Nature 383 (1996), 787–793.
[2] P. Ambrosch and U. Brinck, Detection of nodal micrometastases in head and neck cancer by serial sectioning and immunostaining, Oncology Huntington, 10 (1996), 1221–1229.
[3] P. Ambrosch, M. Kron, G. Fischer and U. Brinck, Micrometastases in carcinoma of the upper aerodigestive tract: detection, risk of metasatizing, and prognostic value of depth of invasion, Head and Neck 17 (1995), 473–479.
[4] R. Arch, K. Wirth, M. Hofmann, H. Pota, S. Matzku, P. Herrlich and M. Zöller, Participation in normal immune response of a metastasis-inducing splice variant of CD44, Science 257 (1992), 682–685.
[5] R. Beschoner, H.P. Horny, U.R. Petrusch and E. Kaiserling, Frequent expression of haemopoietic and non-haemopoietic antigens by reactive plasma cells: an immunohistochemical study using formalin-fixed, paraffin-embedded tissue, Histol. Histopathol. 14 (1999), 805–812.
[6] R.H. Brakenhoff, M. Gerretsen, E.M.C. Knuppels, M. van Dijk, H. van Essen, D.O. Weghuis, R.J. Sinke, G.B. Snow and G.A.M.S. van Dongen, The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion, J. Cell Biol. 129 (1995), 1677–1689.
[7] R.H. Brakenhoff, J.G. Stroomer, C. ten Brink, R. de Bree, H. van Essen, D.O. Weghuis, R.J. Sinke, G.B. Snow and G.A.M.S. van Dongen, Sensitivity, specificity and histologic impact of a E48-peptide vaccine, J. Cell Biol. 129 (1995), 725–733.
[8] R. de Bree, J.C. Roos, J.J. Quak, W. den Hollander, M.W. van den Brekel, J.E. van der Wal, H. Tohi, G.B. Snow and G.A. van Dongen, Clinical imaging of head and neck cancer with technetium-99m-labeled monoclonal antibody E48 IgG or F(ab')2, J. Nucl. Med. 35 (1994), 775–783.
[9] R. de Bree, J.C. Roos, J.J. Quak, W. den Hollander, G.B. Snow and G.A.M.S. van Dongen, Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patient with head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction, Clin. Cancer Res. 5 (1999), 725–733.
M.A.M. van den Brekel, H.V. Stel, P. van der Valk, I. van der Waal, C.J.L.M. Meyer and G.B. Snow, Micrometastases from squamous cell carcinoma in neck dissection specimens, Eur. Arch. Otorhinolaryngol. 249 (1992), 349–353.

M.A.M. van den Brekel, I. van der Waal, C.J.L.M. Meyer, J.L. Freeman, J.A. Castelijns and G.B. Snow, The incidence of micrometastases in neck dissection specimens obtained from elective neck dissections, Laryngoscope 106 (1996), 987–991.

J. A. Brennan, L. Mao, R.H. Hruban, J.O. Boyle, Y.J. Eby, W.M. Koch, S.N. Goodman and D. Sidransky, Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck, N. Engl. J. Med. 332 (1995), 429–435.

J.A. Brennan and D. Sidransky, Molecular staging of head and neck squamous carcinoma, Cancer Metastasis Rev. 15 (1996), 3–10.

M. Bryne, Is the invasive front of an oral carcinoma the most important area for prognostication?, Oral Dis. 4 (1998), 70–77.

M. Bryne, M. Boysen, C.G. Alfsen, V.M. Abeler, J. Sudbo, M.M. Nesland, G.B. Kristensen, J. Piffko and A. Bankfalvi, The invasive front of carcinomas. The most important area for tumour prognoses?, Anticancer Res. 18 (1998), 4757–4764.

M. Bryne, H.S. Koppang, R. Lillegaard and A. Kjærheim, Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value, J. Pathol. 166 (1992), 375–381.

A. Chadburn, G. Inghirami and D.M. Knowles, The kinetics and temporal expression of T-cell activation-associated antigens CD15 (LeuM1), CD30 (Ki-1), EMA and CD11c (LeuM5) by benign activated T cells, Hematol. Pathol. 6 (1992), 193–202.

W.H. Clark Jr, The nature of cancer: Morphogenesis and progressive (self)-disorganization in neoplastic development and progression, Acta Oncol. 34 (1995), 3–21.

J.L. Cordell, B. Falini, W.N. Erber, A.K. Ghosh, Z. Abdulaziz, S. MacDonald, K-A.F. Pulford, G. Stein and D.Y. Mason, Immunoenzymatic labeling of monoclonal antibodies using immunomune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes), J. Histochem. Cytochem. 32 (1984), 219–229.

R.J. Cote, C. Taylor and A.M. Neville, Detection of occult metastases, Cancer J. 8 (1995), 49–51.

G.A. Dent, C.J. Civalier, M.E. Brecher and S.A. Bentley, MUC1 expression in hematopoietic tissues, Am. J. Clin. Pathol. 111 (1999), 741–747.

I.J. Diel and G. Bastert, “Minimal residual disease” beim Mammarkarzinom, in: Onkologie: Gundlagen - Diagnostik - Therapie – Entwicklung, W.J. Zöller, F.X. Bosch and M. Zöller, Expression of CD44 splice variants in epithelial and squamous cell carcinomas of the head and neck, J. Path. 179 (1996), 66–73.

P. Hyckel, H. Kosmehl, A. Berndt, J. Hesse, K.-J. Stillier and Ch. Robottta, Immunohistochemische Demonstration von CD 44 H, CD 44 v3 und CD 44 v6 im oralen Plattenepithelkarzinom, Dtsch. Z. Mund Kiefer GesichtsChir. 19 (1995), 284–289.

A.S. Jones, D.E. Phillips, T.R. Hilliwell and N.J. Roland, Occult node metastases in head and neck squamous carcinoma, Eur. Arch. Otorhinolaryngol. 250 (1993), 446–449.

A.R. Kagan and T.-L. Morgan, Subclinical disease revisited, Amer. J. Clin. Oncol. Cancer Clin. Trials 22 (1999), 621–626.

S. Kita, T. Tsuda, K. Sugisaki, E. Miyazaki and T. Matsumoto, Characterization of distribution of T lymphocyte subsets and activated T lymphocytes infiltrating into sarcoïd lesions, Internat. Medicine 34 (1995), 847–855.
[71] R.P. Takes, R.J.B. de Jong, E. Schuuring, J. Hermans, A.A. Vis, S.V. Litvinov and H.J.M. van Krieken, Markers for assessment of nodal metastasis in laryngeal carcinoma, *Arch. Otolaryngol. Head Neck Surg.* **123** (1997), 412–419.

[72] A.R. Vora, S. Rodgers, A.J. Parker, R. Start, R.C. Rees and A.K. Murray, An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma, *Brit. J. Cancer* **76** (1997), 836–844.

[73] L. Weiss, Metastatic inefficiency, *Advances Cancer Res.* **54** (1990), 159–211.

[74] B. Wittig, C. Schwärzler, N. Fohr, U. Günthert and M. Zöller, Curative treatment of an experimentally induced colitis by a CD44 variant v7-specific antibody, *J. Immunol.* **161** (1998), 1069–1073.

[75] B. Wittig, S. Seiter, N. Föger, C. Schwärzler, U. Günthert and M. Zöller, Functional activity of murine CD44 variant isoforms in allergic and delayed type hypersensitivity, *Immunology Letters* **57** (1997), 217–223.